Drug Trial Radar · NCT06953323
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Jul 10, 2025
Primary completion
Jun 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Wigen Biomedicine Technology (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and efficacy extension (Phase II). The preliminary plan includes seven combination therapy regimens, namely Arm A: WJB001+taxanes (A1: WJB001+paclitaxel, A2: WJB001+albumin paclitaxel); Arm B: WJB001+platinum (B1: WJB001+carboplatin, B2: WJB001+nedaplatin); Arm C: WJB001+paclitaxel+carboplatin; Arm D: WJB001+PARP inhibitor; Arm E: WJB001+VEGF inhibitor; Arm F:WJB001+JS207/JS001(F1:WJB001+JS207,F2:WJB001+JS001);Arm G:WJB001+JS207/JS001+paclitaxel+carboplatin(G1: WJB001+JS207 +paclitaxel+carboplatin;G2:WJB001+JS001+paclitaxel+carboplatin).
Conditions
- Advanced Solid Tumor
Interventions
WJB001 Capsules+Paclitaxel/Paclitaxel-albuminDrug
WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Paclitaxel:80 mg/m2(or 60 mg/m2 ,50 mg/m2), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Paclitaxel-albumin:260mg/m2(220mg/m2,180mg/m2),On day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles
WJB001 Capsules+carboplatin/NedaplatinDrug
WJB001 Capsules:80mg(or160mg, 120mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Carboplatin:AUC 5 mg/ml\*min(or 4mg/ml\*min,3mg/ml\*min), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Nedaplatin:100mg(80mg/m2 ,60mg/m2), Day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles;
WJB001 Capsules+Paclitaxel+carboplatinDrug
WJB001 Capsules:40mg(or 160mg, 120 mg,80mg,60mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Paclitaxel:60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Carboplatin:AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;
WJB001 Capsules+NiraparibDrug
WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Niraparib:Niraparib:300mg(or 200mg,100mg),Oral,QD,Every 21 days;
WJB001 Capsules+BevacizumabDrug
WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Bevacizumab:15mg/kg(or 7.5mg/kg),intravenous infusion, 21 days 1 cycle, up to 22 cycles or unacceptable side effects;
WJB001 Capsules+JS207/JS001Drug
WJB001 Capsules:120mg/160mg ( (or referring to previously conducted cohorts or other clinical studies ),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; JS207:10mg/kg(or lower dosage),intravenous infusion, 21 days 1 cycle, up to 2 years or unacceptable side effects; Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects;
WJB001 Capsules+Paclitaxel+carboplatin+JS207/ToripalimabDrug
WJB001 Capsules:40mg (or referring to previously conducted cohorts or other clinical studies ),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; JS207:10mg/kg(or lower dosage),intravenous infusion, 21 days 1 cycle, up to 2 years or unacceptable side effects Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects Paclitaxel:60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Carboplatin:AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicity (DLT)Time frame: 21day
- Adverse event (AE)Time frame: 3 years
- Serious adverse event (SAE)Time frame: 3 years
- Maximum tolerated dose (MTD)Time frame: 2 years
- Recommended phase II dose (RP2D)Time frame: 2 years
- Objective response rate(ORR)Time frame: 3 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Tumor Hospital Affiliated to Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Sun Yat-sen Hospital, Sun Yat-sen University
Guangzhou, Gunagdong, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.